Willems P H, Van Nooij I G, De Pont J J
Biochim Biophys Acta. 1986 Oct 10;888(3):255-62. doi: 10.1016/0167-4889(86)90223-5.
The putative intracellular calcium antagonist 3,4,5-trimethoxybenzoate 8-(diethylamino)-octyl ester (TMB-8) affects carbachol-induced enzyme secretion from rabbit pancreatic acini in a different way than it does that induced by either the C-terminal octapeptide of cholecystokinin (CCK-8), the phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA) or the calcium ionophore, A23187. In the presence of TMB-8 the dose-response curve for carbachol-induced amylase release shifts to the right, suggesting competitive antagonism at the muscarinic receptor. The hypothesis that TMB-8 acts as a muscarinic receptor antagonist is supported by the observation that TMB-8 dose-dependently inhibits the carbachol-, but not CCK-8-induced increases in cytosolic free calcium, measured in acinar cells by means of the fluorescent calcium indicator quin2. At a concentration of 100 microM, TMB-8 maximally potentiates the secretory response to suboptimal, but not (supra)optimal, concentrations of CCK-8. At the same concentration the drug also potentiates TPA- and A23187-induced enzyme secretion. Cytosolic free calcium levels and CCK-8-induced increases in cytosolic free calcium remain unaffected by 100 microM TMB-8. The above results strongly suggest that potentiation occurs at or beyond the site of interaction between the diacylglycerol- and the Ca2+-activated pathways. At concentrations beyond 100 microM the potentiating effect of TMB-8 declines and, finally, at a concentration of 500 microM the drug completely abolishes the secretory response to CCK-8 and TPA. Basal enzyme secretion, however, remains unaffected. At 500 microM severe side effects are observed as is shown by Trypan blue uptake, lactic dehydrogenase release and release of trapped quin2. It is concluded that at lower concentrations TMB-8 does not act as a specific intracellular calcium antagonist in pancreatic enzyme secretion and that inhibitory effects obtained with rather high concentrations of this drug should be treated with caution.
假定的细胞内钙拮抗剂3,4,5-三甲氧基苯甲酸8-(二乙氨基)辛酯(TMB-8)对卡巴胆碱诱导的兔胰腺腺泡酶分泌的影响方式,与它对胆囊收缩素C末端八肽(CCK-8)、佛波酯12-O-十四酰佛波醇13-乙酸酯(TPA)或钙离子载体A23187诱导的酶分泌的影响方式不同。在TMB-8存在的情况下,卡巴胆碱诱导的淀粉酶释放的剂量-反应曲线向右移动,表明在毒蕈碱受体处存在竞争性拮抗作用。TMB-8作为毒蕈碱受体拮抗剂的假说得到了以下观察结果的支持:TMB-8剂量依赖性地抑制卡巴胆碱诱导的,但不抑制CCK-8诱导的细胞内游离钙增加,这是通过荧光钙指示剂quin2在腺泡细胞中测量的。在100微摩尔浓度下,TMB-8最大程度地增强了对次优但非(超)最优浓度CCK-8的分泌反应。在相同浓度下,该药物也增强了TPA和A23187诱导的酶分泌。细胞内游离钙水平和CCK-8诱导的细胞内游离钙增加不受100微摩尔TMB-8的影响。上述结果强烈表明,增强作用发生在二酰甘油和Ca2+激活途径之间的相互作用位点或其之后。在浓度超过100微摩尔时,TMB-8的增强作用下降,最终,在500微摩尔浓度下,该药物完全消除了对CCK-8和TPA的分泌反应。然而,基础酶分泌不受影响。在500微摩尔时,观察到严重的副作用,如台盼蓝摄取、乳酸脱氢酶释放和被困quin2的释放所示。结论是,在较低浓度下,TMB-8在胰腺酶分泌中不作为特异性细胞内钙拮抗剂,并且用相当高浓度的这种药物获得的抑制作用应谨慎对待